inflammatory bowel disease
News/ News/ Sales and Marketing
AbbVie’s Skyrizi beats IL-23 rivals to Crohn’s disease approval
Phil Taylor
AbbVie, Crohn's disease, inflammatory bowel disease, regulatory approval, Skyrizi
0 Comment
Pfizer’s Arena buyout looks canny, as etrasimod aces phase 3 trials
Phil Taylor
Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, inflammatory bowel disease, Pfizer, ulcerative colitis, Zeposia
0 Comment
Second trial opens door for Lilly’s mirikizumab in ulcerative colitis
Phil Taylor
Eli Lilly, inflammatory bowel disease, mirikizumab, ulcerative colitis
0 Comment
Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s
Phil Taylor
AbbVie, Crohn's disease, inflammatory bowel disease, Rinvoq
0 Comment
Lilly unveils mirikizumab data in ulcerative colitis as it preps filings
Phil Taylor
Eli Lilly, inflammatory bowel disease, mirikizumab, ulcerative colitis
0 Comment
Failed IBD trial dents confidence in BMS’ deucravacitinib
Phil Taylor
Amgen, Bristol-Myers Squibb, deucravacitinib, inflammatory bowel disease, Otezla, ulcerative colitis
0 Comment
Digital/ Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis
Holistic immunology: Supporting patients at every stage of their journey
mike.hammerton@pharmaphorum.com
IMID, inflammatory bowel disease, inflammatory diseases, Janssen, Janssen leaders, psoriasis, Rheumatoid arthritis
0 Comment
News/ News/ Sales and Marketing
Despite biosims, ulcerative colitis drugs still cost too much; ICER
Phil Taylor
AbbVie, gastroenterology, Humira, inflammatory bowel disease, Johnson & Johnson, Merck & Co, Pfizer, Takeda, ulcerative colitis
0 Comment